Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|May 6, 2020
Immuno-oncology-the new paradigm of lung cancer treatmentD E Dawe, C H Harlos, R A JuergensCancer Treatment Reviews|March 24, 2018
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLCB Melosky, Q Chu, R A Juergens, et al.Current Oncology (Toronto, Ont.)|September 25, 2019
Resource use in the last three months of life by lung cancer patients in southern OntarioY Wang, A Van Dam, M Slaven, et al.Current Oncology (Toronto, Ont.)|May 12, 2017
Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspectiveM Cabanero, R Sangha, B S Sheffield, et al.Current Oncology (Toronto, Ont.)|January 5, 2019
Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohortR A Juergens, C Mariano, J Jolivet, et al.Investigational New Drugs|February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignanciesJ Nehra, P A Bradbury, P M Ellis, et al.ESMO Open|February 17, 2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)K He, P M Forde, R Govindan, et al.Pageof 1